Senescent Bone Marrow Cells Sabotage Repair via a Thbs1-Driven Inflammatory Loop

Age-related bone loss is not merely a matter of declining stem cell activity—it is actively sustained by a dysfunctional immune microenvironment within the bone marrow. This study, published in Aging Cell (June 2026), pinpoints thrombospondin-1 (Thbs1) as a master orchestrator of this pathological state, offering one of the most mechanistically complete pictures yet of how senescent stromal cells corrupt immune function and block bone repair.

Using transcriptomic profiling of BMSCs isolated from young (3-month) and aged (24-month) male Sprague-Dawley rats, the authors identified Thbs1 as among the most significantly upregulated senescence-associated secretory phenotype (SASP) factors in aged cells. Aged BMSCs showed classic senescence markers—elevated p16, p21, p53, SA-β-galactosidase activity—and secreted far higher levels of Thbs1 than their young counterparts.

Mechanistically, secreted Thbs1 binds the TGF-β type II receptor (Tgfbr2) on macrophages, triggering Smad3 nuclear translocation. Activated Smad3 directly binds the promoter of Pink1—encoding the mitophagy kinase PINK1—and transcriptionally represses it. Without PINK1, the downstream Parkin-mediated mitophagy pathway stalls, causing damaged mitochondria to accumulate. This results in excessive mitochondrial superoxide generation, redox imbalance, and polarization of macrophages toward the pro-inflammatory M1 phenotype. Restoring PINK1 expression or pharmacologically rescuing mitophagy reversed M1 polarization, confirming causality.

These Thbs1-activated M1 macrophages secrete IL-6, which acts on BMSCs via JAK/STAT3 signaling. Activated STAT3 then directly binds the Thbs1 promoter in BMSCs, amplifying Thbs1 transcription and completing a self-reinforcing loop: senescent BMSC → Thbs1 → macrophage M1 polarization → IL-6 → STAT3 → more Thbs1. Concurrently, IL-6/STAT3 signaling in BMSCs suppresses osteogenic differentiation markers (Runx2, Osteocalcin, Osterix), explaining the dual hit to bone regeneration.

In vivo validation used AAV9 vectors carrying Thbs1 shRNA delivered locally to calvarial bone defects in aged rats. Thbs1 knockdown restored mitochondrial membrane potential and reduced ROS in bone marrow macrophages, promoted a shift from M1 to M2 polarization, upregulated osteogenic gene expression, and significantly enhanced new bone formation as quantified by micro-CT and histology. These effects were not observed in young animals, highlighting the age-specificity of the pathway. The findings position Thbs1 as a tractable therapeutic target—potentially addressable by neutralizing antibodies, small-molecule inhibitors, or gene silencing strategies—for improving fracture healing and implant osseointegration in elderly patients.